Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, <i>EGFR</i>-Mutant, Metastatic Nonsquamous Non-Small Cell Lung Cancer.

21 These results built on a subgroup analysis (n = 124) of EGFR -mutant NSCLC from the phase III IMpower150 study of atezolizumab plus bevacizumab and chemotherapy, which showed a trend toward improved OS versus bevacizumab plus chemotherapy alone. 10 Notably, no OS or PFS benefit was observed with atezolizumab plus chemotherapy (without bevacizumab) versus bevacizumab plus chemotherapy. 10 While these studies suggest an added benefit of anti–VEGF therapy when combined with anti–PD-(L)1 therapy and chemotherapy, there were no statistically significant improvements in OS outcomes.

also in 53,322 other papers